The Architecture of Sight: A New Class of Drugs Aims to Repair Eye Damage

STUART, Fla. – September 15, 2026

Later this week, Eric Schlumpf, the President and CEO of Stuart Therapeutics, will take a seat for a fireside chat at the exclusive Citizens Private Ophthalmology Summit. To the select audience of investors, analysts, and industry leaders, he won’t just be discussing another incremental improvement in eye care. He’ll be evangelizing a fundamental shift in how we approach diseases of the eye: a move away from merely managing symptoms and toward rebuilding the very architecture of sight.

Stuart Therapeutics, a late-stage biopharmaceutical company, is built on a deceptively simple premise: that many chronic eye diseases stem from a common, under-addressed point of failure—the breakdown of collagen. By developing therapeutics designed to repair this foundational protein, the company is positioning itself not as another player in a crowded market, but as a potential pioneer in a new era of regenerative ophthalmology. The presentation offers a strategic window into a technology that aims to mend what is broken, rather than just patching over the cracks.

The Foundation of the Problem: Collagen's Critical Role

To understand the potential of Stuart Therapeutics' approach, one must first appreciate the material at its core. Collagen is the most abundant protein in the human body, serving as the primary structural scaffold for our tissues. In the eye, its helical structures form the extracellular matrix (ECM) of the cornea, sclera, and other critical components, providing the physical integrity and signaling environment necessary for healthy function. This matrix is not static; it is a dynamic system essential for intercellular communication and tissue homeostasis.

In a host of chronic ophthalmic conditions, from the ubiquitous discomfort of dry eye disease to the progressive vision loss of glaucoma, this delicate architecture comes under attack. Enzymes known as matrix metalloproteinases (MMPs), often activated by inflammation and stress, begin to degrade the collagen helices. This degradation disrupts the tissue's structural and signaling roles, creating a vicious cycle of further inflammation and damage. For decades, this foundational point of decay has been considered, as the company notes, "beyond the reach of conventional therapies."

Existing treatments largely focus on the consequences of this breakdown. Anti-inflammatory drugs suppress the immune response, while artificial tears provide temporary lubrication. These are crucial tools for patient comfort and disease management, but they don't address the underlying structural compromise. The innovation Stuart Therapeutics brings to the table is a direct intervention at the site of the damage itself.

A Molecular Blueprint for Repair: The PolyCol™ Platform

At the heart of the company’s pipeline is its proprietary PolyCol™ platform, a technology based on Collagen Mimetic Peptides (CMPs). Licensed from the Wisconsin Alumni Research Foundation (WARF), these synthetic, single-strand polypeptides are designed to act as molecular repair crews. They mimic the amino acid sequences of healthy collagen and are engineered to seek out and bind specifically to the unraveled, damaged sections of the collagen matrix.

By intercalating into these compromised areas, the CMPs effectively "anneal" the fragmented collagen, helping to restore its triple-helical structure. This does more than just patch a hole; it re-establishes the ECM's integrity, which in turn restores proper cell signaling, reduces inflammation, and allows the body's natural healing processes to take over. It’s a mechanism that experts describe as a "novel regenerative therapeutic approach," one that could be truly "disease-modifying" because it targets the root cause of the pathology.

This stands in stark contrast to the current standard of care. "Unlike therapies that focus on suppressing inflammation or supplementing the tear film, CMPs selectively target the fragmented collagen helices without binding to intact fibrils," one researcher familiar with the technology explained. This targeted action promotes the reconstitution of the eye's structural foundation, a fundamentally different strategy that has captured the attention of a specialized corner of the investment world.

The Litmus Test: ST-100 and the Dry Eye Gauntlet

The first major test of this platform is ST-100, the company's lead asset for dry eye disease (DED). The market is enormous and growing, with some analysts projecting it to surpass $16 billion globally by 2033, fueled by an aging population and ever-increasing screen time. Yet, it's a notoriously difficult indication, where even promising drugs can stumble in late-stage trials.

ST-100’s journey has been a case study in the volatile world of biotech. A Phase 2 trial of 160 subjects showed promising results, with the high-dose formulation demonstrating superiority over placebo in improving both corneal staining (a measure of surface damage) and tear production. However, initial results from a subsequent Phase 3 trial, announced in mid-2025, told a more complicated story. The study did not meet its primary endpoint for tear production, a setback attributed in part to an unusually strong placebo performance.

But buried in those results were signals of the drug's unique potential. The trial did show statistically significant improvements in corneal fluorescein staining and visual function within days, highlighting a rapid healing effect on the ocular surface. As CEO Eric Schlumpf acknowledged at the time, "additional study is required." That next step, a Phase 3b trial, is now slated for the first quarter of 2027.

For patients and clinicians, this rapid action is a critical differentiator. "Current dry eye therapies can take weeks or even months to deliver results, and if they work quickly, they are generally uncomfortable," noted one key opinion leader. The ability to provide fast, comfortable relief by directly healing the ocular surface could allow ST-100 to carve out a significant niche in a crowded field, should the next trial prove successful.

Beyond Dry Eye: A Platform for Broader Ophthalmic Restoration

Schlumpf's upcoming discussion at the Citizens summit will almost certainly extend beyond the challenges and promise of ST-100. The true value proposition for investors lies in the breadth of the PolyCol™ platform, which the company states includes over 400 distinct CMP sequences applicable to a wide range of diseases.

Preclinical research has already shown significant potential in other major ophthalmic indications. In studies related to myopia (nearsightedness), topically applied CMPs have demonstrated the ability to repair damaged scleral collagen, restoring tissue stiffness that is critical to halting the disease's progression. For inherited retinal diseases (IRDs), a notoriously complex group of genetic disorders, recent preclinical data showed that a non-gene-specific CMP could preserve retinal thickness and visual function in animal models, suggesting a powerful neuroprotective effect that could be used across multiple conditions.

This platform approach transforms Stuart Therapeutics from a company with a single asset into one with a potentially deep pipeline targeting the fundamental mechanisms of eye disease. Its participation in a private, investor-focused summit is a clear strategic move to communicate this broader vision. The goal is to secure the partnerships and capital needed to not only get ST-100 across the finish line but also to advance its other programs in corneal wound healing, glaucoma, and retinal disease.

While the path through late-stage clinical development is never certain, the science underpinning the PolyCol™ platform represents a compelling new chapter in ophthalmology. The focus on structural repair offers a glimpse of a future where treatment goes beyond management and toward genuine restoration. This week, the financial and strategic gatekeepers of the industry will get a front-row seat to decide if this architectural approach to healing can truly build the future of eye care.